Please wait while the formulary information is being retrieved.
Drug overview for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
Generic name: DESMOPRESSIN (NON-REFRIGERATED) (dess-mow-PRESS-in)
Drug class: Antidiuretic Hormone
Therapeutic class: Endocrine
Desmopressin, a synthetic polypeptide structurally related to arginine vasopressin (antidiuretic hormone), the natural human posterior pituitary hormone, elicits a greater antidiuretic response, on a weight basis, than does arginine vasopressin, and, among other pharmacologic effects, causes a dose-dependent increase in plasma factor VIII (antihemophilic factor) activity.
No enhanced Uses information available for this drug.
Generic name: DESMOPRESSIN (NON-REFRIGERATED) (dess-mow-PRESS-in)
Drug class: Antidiuretic Hormone
Therapeutic class: Endocrine
Desmopressin, a synthetic polypeptide structurally related to arginine vasopressin (antidiuretic hormone), the natural human posterior pituitary hormone, elicits a greater antidiuretic response, on a weight basis, than does arginine vasopressin, and, among other pharmacologic effects, causes a dose-dependent increase in plasma factor VIII (antihemophilic factor) activity.
No enhanced Uses information available for this drug.
DRUG IMAGES
DESMOPRESSIN 10 MCG/0.1 ML SPR
The following indications for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)) have been approved by the FDA:
Indications:
Partial central diabetes insipidus
Professional Synonyms:
Partial ADH deficiency induced diabetes insipidus
Partial neurogenic diabetes insipidus
Partial neurohypophyseal diabetes insipidus
Partial pituitary diabetes insipidus
Partial vasopressin-sensitive diabetes insipidus
Indications:
Partial central diabetes insipidus
Professional Synonyms:
Partial ADH deficiency induced diabetes insipidus
Partial neurogenic diabetes insipidus
Partial neurohypophyseal diabetes insipidus
Partial pituitary diabetes insipidus
Partial vasopressin-sensitive diabetes insipidus
The following dosing information is available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
For the management of neurohypophyseal diabetes insipidus, the usual adult maintenance dosage of desmopressin acetate recommended by the manufacturer is 10-40 mcg (0.1-0.4 mL or 1-4 sprays from the spray pump of a solution containing 0.1 mg/mL) given intranasally in 1-3 divided doses daily. Some clinicians have recommended an adult desmopressin acetate maintenance dosage of 5-40 mcg (0.05-0.4 mL of a solution containing 0.1 mg/mL). Most adults require 20 mcg daily administered in 2 divided doses in the morning and the evening.
In children 3 months to 12 years of age, the initial dose of desmopressin acetate is 5 mcg or less (0.05 mL of a solution containing 0.1 mg/mL) administered intranasally in the evening. In children 3 months to 12 years of age, the usual intranasal dosage is 5-30 mcg (0.05-0.3 mL of a solution containing 0.1 mg/mL) daily in a single evening dose or divided in 2 doses. About 25-33% of adults and children can be controlled with a single daily dose.
The lowest effective dosage should be used. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
If the drug is administered by subcutaneous or direct IV injection in adults or children 12 years of age or older for the management of diabetes insipidus, the usual maintenance dosage is 2-4 mcg daily given in 2 divided doses. The parenteral dosage for the management of diabetes insipidus in children younger than 12 years of age has not been established. Patients with diabetes insipidus being switched from intranasal to subcutaneous or IV administration of the drug should generally receive one-tenth their maintenance intranasal dosage parenterally.
The lowest effective parenteral dosage should be given. During long-term use, patients rarely may develop tolerance to the drug and require cautious increase in dosage to achieve an adequate therapeutic response. Fluid intake should be restricted.
.)
If oral desmopressin acetate is used for the management of diabetes insipidus in patients who previously received the drug intranasally, oral therapy should be initiated 12 hours after the last intranasal dose. The usual initial oral dosage of desmopressin acetate for adults and pediatric patients is 0.05 mg twice daily, and subsequent dosage should be adjusted according to response.
In clinical studies, the optimal dosage range for most patients was 0.1-0.8 mg daily given in divided doses.
Each dose should be adjusted separately for an adequate diurnal rhythm of water turnover. Total oral daily dosage should be increased or decreased in the range of 0.1-1.2
mg divided into 2 or 3 daily doses as needed to obtain adequate antidiuresis. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
In children 3 months to 12 years of age, the initial dose of desmopressin acetate is 5 mcg or less (0.05 mL of a solution containing 0.1 mg/mL) administered intranasally in the evening. In children 3 months to 12 years of age, the usual intranasal dosage is 5-30 mcg (0.05-0.3 mL of a solution containing 0.1 mg/mL) daily in a single evening dose or divided in 2 doses. About 25-33% of adults and children can be controlled with a single daily dose.
The lowest effective dosage should be used. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
If the drug is administered by subcutaneous or direct IV injection in adults or children 12 years of age or older for the management of diabetes insipidus, the usual maintenance dosage is 2-4 mcg daily given in 2 divided doses. The parenteral dosage for the management of diabetes insipidus in children younger than 12 years of age has not been established. Patients with diabetes insipidus being switched from intranasal to subcutaneous or IV administration of the drug should generally receive one-tenth their maintenance intranasal dosage parenterally.
The lowest effective parenteral dosage should be given. During long-term use, patients rarely may develop tolerance to the drug and require cautious increase in dosage to achieve an adequate therapeutic response. Fluid intake should be restricted.
.)
If oral desmopressin acetate is used for the management of diabetes insipidus in patients who previously received the drug intranasally, oral therapy should be initiated 12 hours after the last intranasal dose. The usual initial oral dosage of desmopressin acetate for adults and pediatric patients is 0.05 mg twice daily, and subsequent dosage should be adjusted according to response.
In clinical studies, the optimal dosage range for most patients was 0.1-0.8 mg daily given in divided doses.
Each dose should be adjusted separately for an adequate diurnal rhythm of water turnover. Total oral daily dosage should be increased or decreased in the range of 0.1-1.2
mg divided into 2 or 3 daily doses as needed to obtain adequate antidiuresis. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
Desmopressin acetate is administered intranasally, orally, by subcutaneous injection, direct IV injection, or slow IV infusion.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DESMOPRESSIN 10 MCG/0.1 ML SPR | Maintenance | Adults spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DESMOPRESSIN 10 MCG/0.1 ML SPR | Maintenance | Adults spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening |
The following drug interaction information is available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
There are 2 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Desmopressin/Glucocorticoids SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Glucocorticoids increase the risk of hyponatremia.(1-4) CLINICAL EFFECTS: Concurrent use of glucocorticoids may increase the risk of hyponatremia with desmopressin.(1-4) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, lamotrigine, loop diuretics, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants). PATIENT MANAGEMENT: The concurrent use of systemic or inhaled glucocorticoids with desmopressin is contraindicated.(1-4) Desmopressin may be initiated 3 days or 5 half-lives after glucocorticoid discontinuation, whichever is longer. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
ADVAIR DISKUS, ADVAIR HFA, AGAMREE, AIRDUO DIGIHALER, AIRDUO RESPICLICK, AIRSUPRA, ALKINDI SPRINKLE, ALVESCO, ANALPRAM HC, ANUCORT-HC, ANUSOL-HC, ARMONAIR DIGIHALER, ARNUITY ELLIPTA, ASMANEX, ASMANEX HFA, BECLOMETHASONE DIPROPIONATE, BETA 1, BETALOAN SUIK, BETAMETHASONE ACETATE MICRO, BETAMETHASONE ACETATE-SOD PHOS, BETAMETHASONE DIPROPIONATE, BETAMETHASONE SOD PHOS-ACETATE, BETAMETHASONE SOD PHOS-WATER, BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE VALERATE, BREO ELLIPTA, BREYNA, BREZTRI AEROSPHERE, BSP 0820, BUDESONIDE, BUDESONIDE DR, BUDESONIDE EC, BUDESONIDE ER, BUDESONIDE MICRONIZED, BUDESONIDE-FORMOTEROL FUMARATE, BUPIVACAINE-DEXAMETH-EPINEPHRN, CELESTONE, CLOBETASOL PROPIONATE MICRO, CORTEF, CORTENEMA, CORTIFOAM, CORTISONE ACETATE, DEFLAZACORT, DEPO-MEDROL, DESONIDE MICRONIZED, DESOXIMETASONE, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DMT SUIK, DOUBLEDEX, DULERA, EMFLAZA, EOHILIA, FLUNISOLIDE, FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE MICRO, FLUOCINONIDE MICRONIZED, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE HFA, FLUTICASONE PROPIONATE MICRO, FLUTICASONE-SALMETEROL, FLUTICASONE-SALMETEROL HFA, FLUTICASONE-VILANTEROL, HEMADY, HEMMOREX-HC, HEXATRIONE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE SOD SUCCINATE, HYDROCORTISONE-PRAMOXINE, KENALOG-10, KENALOG-40, KENALOG-80, LIDOCAINE-HYDROCORTISONE, LIDOCIDEX-I, MAS CARE-PAK, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MILLIPRED, MILLIPRED DP, MOMETASONE FUROATE, ORAPRED ODT, ORTIKOS, PEDIAPRED, PREDNISOLONE, PREDNISOLONE ACETATE MICRONIZE, PREDNISOLONE MICRONIZED, PREDNISOLONE SODIUM PHOS ODT, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE, PREDNISONE INTENSOL, PREDNISONE MICRONIZED, PRO-C-DURE 5, PRO-C-DURE 6, PROCORT, PROCTOCORT, PROCTOFOAM-HC, PULMICORT, PULMICORT FLEXHALER, QVAR REDIHALER, RAYOS, SOLU-CORTEF, SOLU-MEDROL, SYMBICORT, TAPERDEX, TARPEYO, TRELEGY ELLIPTA, TRIAMCINOLONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE MICRO, TRILOAN II SUIK, TRILOAN SUIK, UCERIS, VERIPRED 20, WIXELA INHUB, ZCORT, ZILRETTA, ZYPRAM |
| Desmopressin/Loop Diuretics SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Loop diuretics increase the risk of hyponatremia.(1-4) CLINICAL EFFECTS: Concurrent use of loop diuretics may increase the risk of hyponatremia with desmopressin.(1-4) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants). PATIENT MANAGEMENT: The concurrent use of loop diuretics with desmopressin is contraindicated.(1-4) If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
BUMETANIDE, EDECRIN, ETHACRYNATE SODIUM, ETHACRYNIC ACID, FUROSCIX, FUROSEMIDE, FUROSEMIDE-0.9% NACL, LASIX, SOAANZ, TORSEMIDE |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Erdafitinib/Serum Phosphate Level-Altering Drugs SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Medications that alter serum phosphate may interfere with interpretation of phosphate levels that are needed to determine initial erdafitinib dose.(1) CLINICAL EFFECTS: Serum phosphate levels that are elevated by concomitant medications may result in an inappropriately low dose and decreased effectiveness of erdafitinib. Serum phosphate levels that are decreased by concomitant medications may result in an inappropriately high dose and increased toxicity from erdafitinib. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of erdafitinib states that agents that alter serum phosphate levels should be avoided before the initial dose increase period for erdafitinib based on serum phosphate levels (days 14 to 21).(1) DISCUSSION: Concomitant administration of serum phosphate level-altering agents during the initial dose increase period of erdafitinib based on serum phosphate levels (days 14 to 21) may interfere with serum phospate levels and lead to incorrect dosing of erdafitinib.(1) Agents that may alter serum phosphate levels linked to this monograph include: aluminum carbonate, aluminum hydroxide, calcium acetate, calcium carbonate, calcium citrate, cod liver oil, ferric citrate, lanthanum, magnesium carbonate, magnesium hydroxide, potassium phosphate, sevelamer, sodium phosphate, sucroferric oxyhydroxide, tenapanor, and vitamin D.(1) |
BALVERSA |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Desmopressin/Agents with Hyponatremia Risk SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Carbamazepine, chlorpromazine, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants increase the risk of hyponatremia.(1-3) CLINICAL EFFECTS: Concurrent use may increase the risk of hyponatremia with desmopressin.(1-3) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (glucocorticoids, loop diuretics). PATIENT MANAGEMENT: The concurrent use of agents with a risk of hyponatremia with desmopressin may increase the risk of hyponatremia. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
ACCURETIC, ACETAMIN-CAFF-DIHYDROCODEINE, ACETAMINOPHEN-CODEINE, AMILORIDE-HYDROCHLOROTHIAZIDE, AMITRIPTYLINE HCL, AMLODIPINE-VALSARTAN-HCTZ, AMOXAPINE, ANAFRANIL, ANAPROX DS, ANJESO, APADAZ, ARTHROTEC 50, ARTHROTEC 75, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, ATACAND HCT, ATENOLOL-CHLORTHALIDONE, AVALIDE, BELBUCA, BELLADONNA-OPIUM, BENAZEPRIL-HYDROCHLOROTHIAZIDE, BENICAR HCT, BENZHYDROCODONE-ACETAMINOPHEN, BISOPROLOL-HYDROCHLOROTHIAZIDE, BRIXADI, BROMFENAC SODIUM, BUPIVACAINE-KETOROLAC-KETAMINE, BUPRENORPHINE, BUPRENORPHINE HCL, BUPRENORPHINE-NALOXONE, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTORPHANOL TARTRATE, BUTRANS, CALDOLOR, CAMBIA, CANDESARTAN-HYDROCHLOROTHIAZID, CAPTOPRIL-HYDROCHLOROTHIAZIDE, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CARISOPRODOL-ASPIRIN-CODEINE, CELEBREX, CELECOXIB, CELEXA, CHLORDIAZEPOXIDE-AMITRIPTYLINE, CHLOROTHIAZIDE, CHLOROTHIAZIDE SODIUM, CHLORPROMAZINE HCL, CHLORTHALIDONE, CITALOPRAM HBR, CLOMIPRAMINE HCL, CODEINE PHOSPHATE, CODEINE SULFATE, COMBOGESIC, COMBOGESIC IV, CONSENSI, CONZIP, COXANTO, DAYPRO, DEMEROL, DESIPRAMINE HCL, DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM ER, DICLOFENAC SODIUM MICRONIZED, DICLOFENAC SODIUM-MISOPROSTOL, DIFLUNISAL, DIHYDROCODEINE BITARTRATE, DILAUDID, DIOVAN HCT, DIPHENOXYLATE-ATROPINE, DISKETS, DIURIL, DOLOBID, DOXEPIN HCL, DSUVIA, DURAMORPH, EC-NAPROSYN, EDARBYCLOR, ELYXYB, ENALAPRIL-HYDROCHLOROTHIAZIDE, ENDOCET, EPITOL, EQUETRO, ESCITALOPRAM OXALATE, ETODOLAC, ETODOLAC ER, EXFORGE HCT, FELDENE, FENOPROFEN CALCIUM, FENOPRON, FENTANYL, FENTANYL CITRATE, FENTANYL CITRATE-0.9% NACL, FENTANYL CITRATE-D5W, FENTANYL CITRATE-STERILE WATER, FENTANYL CITRATE-WATER, FENTANYL-BUPIVACAINE-0.9% NACL, FENTANYL-BUPIVACAINE-NACL, FENTANYL-ROPIVACAINE-0.9% NACL, FENTANYL-ROPIVACAINE-NACL, FIORICET WITH CODEINE, FLUOXETINE DR, FLUOXETINE HCL, FLURBIPROFEN, FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE ER, FOSINOPRIL-HYDROCHLOROTHIAZIDE, HEMICLOR, HYCODAN, HYDROCHLOROTHIAZIDE, HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE ER, HYDROCODONE-ACETAMINOPHEN, HYDROCODONE-CHLORPHENIRAMNE ER, HYDROCODONE-HOMATROPINE MBR, HYDROCODONE-IBUPROFEN, HYDROMET, HYDROMORPHONE ER, HYDROMORPHONE HCL, HYDROMORPHONE HCL-0.9% NACL, HYDROMORPHONE HCL-D5W, HYDROMORPHONE HCL-NACL, HYDROMORPHONE HCL-WATER, HYSINGLA ER, HYZAAR, IBU, IBUPAK, IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN-FAMOTIDINE, IMIPRAMINE HCL, IMIPRAMINE PAMOATE, INDAPAMIDE, INDOCIN, INDOMETHACIN, INDOMETHACIN ER, INFLAMMACIN, INFLATHERM(DICLOFENAC-MENTHOL), INFUMORPH, INZIRQO, IRBESARTAN-HYDROCHLOROTHIAZIDE, KETOPROFEN, KETOPROFEN MICRONIZED, KETOROLAC TROMETHAMINE, KIPROFEN, LAMICTAL, LAMICTAL (BLUE), LAMICTAL (GREEN), LAMICTAL (ORANGE), LAMICTAL ODT, LAMICTAL ODT (BLUE), LAMICTAL ODT (GREEN), LAMICTAL ODT (ORANGE), LAMICTAL XR, LAMICTAL XR (BLUE), LAMICTAL XR (GREEN), LAMICTAL XR (ORANGE), LAMOTRIGINE, LAMOTRIGINE (BLUE), LAMOTRIGINE (GREEN), LAMOTRIGINE (ORANGE), LAMOTRIGINE ER, LAMOTRIGINE ODT, LAMOTRIGINE ODT (BLUE), LAMOTRIGINE ODT (GREEN), LAMOTRIGINE ODT (ORANGE), LEVORPHANOL TARTRATE, LEXAPRO, LISINOPRIL-HYDROCHLOROTHIAZIDE, LODINE, LOFENA, LOMOTIL, LOSARTAN-HYDROCHLOROTHIAZIDE, LOTENSIN HCT, LURBIPR, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, MEPERIDINE HCL, MEPERIDINE HCL-0.9% NACL, METHADONE HCL, METHADONE HCL-0.9% NACL, METHADONE HCL-NACL, METHADONE INTENSOL, METHADOSE, METHYLDOPA-HYDROCHLOROTHIAZIDE, METOLAZONE, METOPROLOL-HYDROCHLOROTHIAZIDE, MICARDIS HCT, MITIGO, MORPHINE SULFATE, MORPHINE SULFATE ER, MORPHINE SULFATE-0.9% NACL, MORPHINE SULFATE-NACL, MOTOFEN, MS CONTIN, NABUMETONE, NABUMETONE MICRONIZED, NALBUPHINE HCL, NALFON, NALOCET, NAPRELAN, NAPROSYN, NAPROTIN, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM CR, NAPROXEN SODIUM ER, NAPROXEN-ESOMEPRAZOLE MAG, NEOPROFEN, NORPRAMIN, NORTRIPTYLINE HCL, NUCYNTA, NUCYNTA ER, OLANZAPINE-FLUOXETINE HCL, OLMESARTAN-AMLODIPINE-HCTZ, OLMESARTAN-HYDROCHLOROTHIAZIDE, OPIUM TINCTURE, OXAPROZIN, OXYCODONE HCL, OXYCODONE HCL ER, OXYCODONE HYDROCHLORIDE, OXYCODONE-ACETAMINOPHEN, OXYCONTIN, OXYMORPHONE HCL, OXYMORPHONE HCL ER, PAMELOR, PAROXETINE CR, PAROXETINE ER, PAROXETINE HCL, PAROXETINE MESYLATE, PAXIL, PAXIL CR, PENTAZOCINE-NALOXONE HCL, PERCOCET, PERPHENAZINE-AMITRIPTYLINE, PHENYLBUTAZONE, PIROXICAM, PRIMLEV, PROLATE, PROMETHAZINE-CODEINE, PROPRANOLOL-HYDROCHLOROTHIAZID, PROTRIPTYLINE HCL, PROZAC, QDOLO, QUINAPRIL-HYDROCHLOROTHIAZIDE, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RELAFEN DS, REMIFENTANIL HCL, ROPIVACAINE-CLONIDINE-KETOROLC, ROPIVACAINE-KETOROLAC-KETAMINE, ROXICODONE, ROXYBOND, SERTRALINE HCL, SILENOR, SPIRONOLACTONE-HCTZ, SPRIX, SUBLOCADE, SUBOXONE, SUBVENITE, SUBVENITE (BLUE), SUBVENITE (GREEN), SUBVENITE (ORANGE), SUFENTANIL CITRATE, SULINDAC, SUMATRIPTAN SUCC-NAPROXEN SOD, SYMBRAVO, TEGRETOL, TEGRETOL XR, TELMISARTAN-HYDROCHLOROTHIAZID, TENORETIC 100, TENORETIC 50, THALITONE, TOLECTIN 600, TOLMETIN SODIUM, TORONOVA II SUIK, TORONOVA SUIK, TOXICOLOGY SALIVA COLLECTION, TRAMADOL HCL, TRAMADOL HCL ER, TRAMADOL HCL-ACETAMINOPHEN, TRESNI, TREXIMET, TREZIX, TRIAMTERENE-HYDROCHLOROTHIAZID, TRIBENZOR, TRICHLORMETHIAZIDE, TRIMIPRAMINE MALEATE, TUXARIN ER, ULTIVA, VALSARTAN-HYDROCHLOROTHIAZIDE, VASERETIC, VIBERZI, VIMOVO, VIVLODEX, XTAMPZA ER, ZESTORETIC, ZIPSOR, ZOLOFT, ZORVOLEX, ZUBSOLV, ZYNRELEF |
The following contraindication information is available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 4 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
There are 4 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Hyponatremia |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Psychogenic polydipsia |
| Severe allergic rhinitis |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Allergic rhinitis |
| Chronic heart failure |
| Coronary artery disease |
| Cystic fibrosis |
| Hypertension |
The following adverse reaction information is available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 8 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Hypertension |
| Rare/Very Rare |
|---|
|
Acute respiratory failure Anaphylaxis Atrial fibrillation Chest pain Hyponatremia Seizure disorder Water intoxication |
There are 29 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abdominal pain with cramps Back pain Body fluid retention Bronchitis Chills Dizziness Epistaxis Headache disorder Nasal passage irritation Nausea Sneezing Vulvodynia |
| Rare/Very Rare |
|---|
|
Agitation Balanitis Cough Drowsy Dyspepsia Dysuria Edema Flushing Insomnia Nasal congestion Ocular itching Palpitations Rhinitis Sore throat Tachycardia Upper respiratory infection Vomiting |
The following precautions are available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated)):
WARNING: Desmopressin can rarely cause a low level of sodium in the blood (hyponatremia), which can be serious or even fatal. Drinking too much liquid, using certain medications (such as "water pills"/diuretics including furosemide, corticosteroids such as prednisone), being 65 years or older, or having certain medical conditions may increase the risk of low sodium in the blood. Lab tests (such as urine tests, sodium blood levels) must be done before you start using this medication and while you are using it.
Keep all medical and lab appointments. Tell your doctor right away if you develop symptoms of low sodium in the blood, such as nausea, vomiting, headache, muscle weakness/cramps, unusual tiredness, unusual drowsiness, dizziness, restlessness, mental/mood changes including confusion/irritability. Get medical help right away if you have any very serious side effects, including seizure or trouble breathing.
WARNING: Desmopressin can rarely cause a low level of sodium in the blood (hyponatremia), which can be serious or even fatal. Drinking too much liquid, using certain medications (such as "water pills"/diuretics including furosemide, corticosteroids such as prednisone), being 65 years or older, or having certain medical conditions may increase the risk of low sodium in the blood. Lab tests (such as urine tests, sodium blood levels) must be done before you start using this medication and while you are using it.
Keep all medical and lab appointments. Tell your doctor right away if you develop symptoms of low sodium in the blood, such as nausea, vomiting, headache, muscle weakness/cramps, unusual tiredness, unusual drowsiness, dizziness, restlessness, mental/mood changes including confusion/irritability. Get medical help right away if you have any very serious side effects, including seizure or trouble breathing.
The following icd codes are available for DESMOPRESSIN ACETATE (desmopressin (non-refrigerated))'s list of indications:
| Partial central diabetes insipidus | |
| E23.2 | Diabetes insipidus |
Formulary Reference Tool